Mondrian Investment Partners LTD Boosts Position in Meridian Bioscience Inc. (NASDAQ:VIVO)
Mondrian Investment Partners LTD increased its stake in shares of Meridian Bioscience Inc. (NASDAQ:VIVO) by 18.6% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 177,739 shares of the company’s stock after buying an additional 27,848 shares during the period. Mondrian Investment Partners LTD’s holdings in Meridian Bioscience were worth $2,799,000 as of its most recent filing with the SEC.
Other large investors also recently bought and sold shares of the company. Wells Fargo & Company MN raised its stake in shares of Meridian Bioscience by 50.2% in the first quarter. Wells Fargo & Company MN now owns 767,606 shares of the company’s stock valued at $10,593,000 after buying an additional 256,571 shares during the last quarter. Clark Estates Inc. NY acquired a new stake in shares of Meridian Bioscience during the first quarter valued at about $3,133,000. FMR LLC raised its stake in shares of Meridian Bioscience by 148.5% in the first quarter. FMR LLC now owns 353,141 shares of the company’s stock valued at $4,873,000 after buying an additional 211,023 shares during the last quarter. State Street Corp raised its stake in shares of Meridian Bioscience by 15.2% in the first quarter. State Street Corp now owns 1,243,847 shares of the company’s stock valued at $17,164,000 after buying an additional 163,770 shares during the last quarter. Finally, Dean Investment Associates LLC raised its stake in shares of Meridian Bioscience by 60.9% in the first quarter. Dean Investment Associates LLC now owns 413,745 shares of the company’s stock valued at $5,710,000 after buying an additional 156,625 shares during the last quarter. 85.83% of the stock is currently owned by institutional investors and hedge funds.
Shares of Meridian Bioscience Inc. (VIVO) opened at 13.75 on Friday. The firm has a market capitalization of $580.28 million, a price-to-earnings ratio of 27.50 and a beta of 0.89. Meridian Bioscience Inc. has a 52 week low of $10.75 and a 52 week high of $19.85. The firm has a 50-day moving average of $14.84 and a 200 day moving average of $13.99.
Meridian Bioscience (NASDAQ:VIVO) last released its quarterly earnings data on Thursday, July 27th. The company reported $0.16 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.16. Meridian Bioscience had a net margin of 10.77% and a return on equity of 16.93%. The firm had revenue of $50.14 million for the quarter, compared to analyst estimates of $49.13 million. During the same period last year, the firm earned $0.21 earnings per share. The business’s quarterly revenue was down 1.0% compared to the same quarter last year. On average, equities analysts predict that Meridian Bioscience Inc. will post $0.67 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, August 17th. Shareholders of record on Monday, August 7th will be paid a $0.125 dividend. This represents a $0.50 dividend on an annualized basis and a dividend yield of 3.64%. The ex-dividend date is Thursday, August 3rd. Meridian Bioscience’s dividend payout ratio (DPR) is 98.04%.
TRADEMARK VIOLATION NOTICE: This piece was reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/mondrian-investment-partners-ltd-boosts-position-in-meridian-bioscience-inc-nasdaqvivo/1477993.html.
Several brokerages have issued reports on VIVO. BidaskClub lowered shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Zacks Investment Research lowered shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Finally, Canaccord Genuity lifted their price target on shares of Meridian Bioscience from $13.00 to $15.00 and gave the company a “hold” rating in a research note on Wednesday, May 3rd. Three research analysts have rated the stock with a sell rating and four have assigned a hold rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $14.75.
About Meridian Bioscience
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience Inc. (NASDAQ:VIVO).
Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.